| Identification | Back Directory | [Name]
RSV604 | [CAS]
676128-63-5 | [Synonyms]
RSV604
CS-2092
RSV604;RSV 604
Urea, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(2-fluorophenyl)-
(S)-1-(2-fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea | [Molecular Formula]
C22H17FN4O2 | [MDL Number]
MFCD28963952 | [MOL File]
676128-63-5.mol | [Molecular Weight]
388.39 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 30 mg/ml; DMF:PBS (pH 7.2) (1:20): 0.04 mg/ml; DMSO: 20 mg/ml; Ethanol: 5 mg/ml | [form ]
A solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
RSV604 (A-60444), a novel benzodiazepine, is an inhibitor of respiratory syncytial virus (RSV) with EC50 of 0.86 μM. It has the potential to treat RSV-related diseases. Phase 2. | [in vitro]
RSV604 (5 days) inhibits the growth of four laboratory strains of RSV (RSS, Long, A2 and B), with EC 50 s ranging from 0.5 to 0.9 μM in plaque reduction assay.
It (6 days) inhibits RSV-induced HEp-2 cell death, with an EC 50 of 0.86 μM.
Also RSV604 (3 days) reduces viral antigen synthesis in RSV-infected HEp-2 cells, with an EC 50 of 1.7 μM.
RSV604 (1-20 μM; 7 days) dose-dependently inhibits RSV infection in human airway epithelial (HAE) cells, with no gross cytotoxicity, leakage of basolateral fluid to the apical surface, or alteration of cilium beat frequency. | [target]
| Target | Value | RSV
(Cell-free assay) | 0.86 μM(EC50) |
|
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|